Susan C. Weil

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

Raffit Hassan, Steven J. Cohen, Martin D. Phillips et al. · Clinical Cancer Research · 2010 · 199 citations · Full text

Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study

Jason Konner, Katherine M. Bell‐McGuinn, Paul Sabbatini et al. · Clinical Cancer Research · 2010 · 157 citations

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer

Deborah K. Armstrong, Allen J. White, Susan C. Weil et al. · Gynecologic Oncology · 2013 · 149 citations

Medicine, Folate Receptor Alpha, Pathology +7

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

Ignace Vergote, Deborah K. Armstrong, Giovanni Scambia et al. · Journal of Clinical Oncology · 2016 · 149 citations · Full text

Changes in RNA metabolism and accumulation of presumptive messenger RNA during transition from the growing to the quiescent state of cultured mouse fibroblasts

P S Rudland, Susan C. Weil, A. R. Hunter · Journal of Molecular Biology · 1975 · 108 citations

Rna Metabolism, Developmental Biology, Rna Biology +8